Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regulus Therapeutics

3.49
+0.730026.45%
Pre-market: 3.490.00000.00%04:03 EDT
Volume:4.77M
Turnover:16.13M
Market Cap:231.19M
PE:-4.24
High:3.73
Open:2.78
Low:2.76
Close:2.76
Loading ...

Regulus: Q4 Earnings Snapshot

Associated Press Finance
·
14 Mar

Regulus Therapeutics Q4 2024 GAAP EPS $(0.20) Beats $(0.21) Estimate

Benzinga
·
14 Mar

Regulus Therapeutics: Co Expects Its Cash Runway to Extend Into Early 2026

THOMSON REUTERS
·
14 Mar

Regulus Therapeutics Q4 Operating Expenses USD 13.746 Million

THOMSON REUTERS
·
14 Mar

Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates

PR Newswire
·
14 Mar

Regulus Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
26 Feb

Regulus Therapeutics Inc. (RGLS): Among the Cheapest Stocks Insiders Are Buying Recently

Insider Monkey
·
21 Feb

Insiders Give Up US$8.7k As Regulus Therapeutics Stock Drops To US$1.00

Simply Wall St.
·
02 Feb

Analysts Offer Insights on Healthcare Companies: Regulus (RGLS) and Roche Holding AG (OtherRHHVF)

TIPRANKS
·
31 Jan

Regulus Therapeutics Shares Drop 24% Despite Positive ADPKD Trial Data

GuruFocus.com
·
30 Jan

Regulus Therapeutics Kidney Disease Treatment Shows Response in Early-stage Trial -- Shares Fall

MT Newswires Live
·
30 Jan

Regulus Therapeutics Inc - Imaging-Based Biomarkers Show Reduction in Kidney Volume Growth Rate

THOMSON REUTERS
·
29 Jan

Regulus Therapeutics Inc - Phase 1B Trial Shows Continued Mechanistic Dose Response

THOMSON REUTERS
·
29 Jan

Regulus Therapeutics Announces Positive Clinical and Regulatory Updates From Its Autosomal Dominant Polycystic Kidney Disease (Adpkd) Program for Farabursen (Rgls8429)

THOMSON REUTERS
·
29 Jan

Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)

PR Newswire
·
29 Jan

With 64% institutional ownership, Regulus Therapeutics Inc. (NASDAQ:RGLS) is a favorite amongst the big guns

Simply Wall St.
·
08 Dec 2024

Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences

PR Newswire
·
26 Nov 2024

Regulus Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
11 Nov 2024

Buy Rating for Regulus Therapeutics Driven by Promising Clinical and Regulatory Prospects for RGLS8429

TIPRANKS
·
11 Nov 2024

Regulus Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary

Reuters
·
08 Nov 2024